Philippe Archinard
Director/Board Member presso GENEURO SA
Patrimonio netto: 3 383 $ in data 29/02/2024
Profilo
Philippe Archinard is a French businessperson who has been the head of 7 different companies and holds the position of Chairman at BioAster and Chairman-Supervisory Board at Fabentech SAS.
Dr. Archinard is also Deputy CEO-Innovation & Scientific Partnerships at Institut Mérieux SA and on the board of 11 other companies.
Philippe Archinard previously occupied the position of Chairman of Lyonbiopôle, Chairman at bioMérieux, Inc., Chief Executive Officer for TSGH SAS and Chief Executive Officer for Fujirebio Europe NV.
He received a doctorate and an undergraduate degree from the University of Lyon and an undergraduate degree from Harvard Business School.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
31/12/2022 | 1 030 ( 0.02% ) | 3 383 $ | 29/02/2024 |
Posizioni attive di Philippe Archinard
Società | Posizione | Inizio |
---|---|---|
TRANSGENE | Director/Board Member | 01/12/2020 |
BIOMÉRIEUX | Director/Board Member | 01/01/2005 |
NH THERAGUIX SAS | Director/Board Member | 22/02/2019 |
GENEURO SA | Director/Board Member | 27/05/2021 |
PHAXIAM THERAPEUTICS S.A. | Director/Board Member | 23/06/2023 |
Transgene, Inc. | Director/Board Member | - |
Jalon Therapeutics
Jalon Therapeutics Pharmaceuticals: MajorHealth Technology Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison. | Director/Board Member | - |
bioMERIEUX Benelux SANV
bioMERIEUX Benelux SANV Medical SpecialtiesHealth Technology bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium | Director/Board Member | 10/06/2010 |
Fabentech SAS
Fabentech SAS Medical/Nursing ServicesHealth Services Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France. | Chairman | - |
░░░░░░░░ ░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
░░░░░░░░ | ░░░░░░░░ | - |
Precedenti posizioni note di Philippe Archinard
Società | Posizione | Fine |
---|---|---|
░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░ ░░ ░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░ ░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Philippe Archinard
University of Lyon | Doctorate Degree |
Harvard Business School | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
TRANSGENE | Health Technology |
BIOMÉRIEUX | Health Technology |
GENEURO SA | Health Technology |
PHAXIAM THERAPEUTICS S.A. | Health Technology |
Aziende private | 17 |
---|---|
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Health Technology |
TSGH SAS
TSGH SAS Financial ConglomeratesFinance TSGH SAS operates as an investment holding company. The company is headquartered in Lyon, France. | Finance |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | Health Technology |
bioMérieux, Inc.
bioMérieux, Inc. Medical SpecialtiesHealth Technology bioMérieux, Inc. develops in-vitro diagnostics solutions. It offers microbiological testing solutions for medical and industrial applications. The company was founded on December 31, 1986 and is headquartered in Durham, NC. | Health Technology |
Advanced BioScience Laboratories, Inc.
Advanced BioScience Laboratories, Inc. Medical/Nursing ServicesHealth Services Advanced BioScience Laboratories, Inc. provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. It focuses on the development of therapeutics, vaccines, and other biologic products. The company was founded in 1961 and is headquartered in Rockville, MD. | Health Services |
bioMERIEUX Benelux SANV
bioMERIEUX Benelux SANV Medical SpecialtiesHealth Technology bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium | Health Technology |
Institut Mérieux SA
Institut Mérieux SA BiotechnologyHealth Technology Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France. | Health Technology |
Synergie Lyon Cancer
Synergie Lyon Cancer Miscellaneous Commercial ServicesCommercial Services Synergie Lyon Cancer provides health care services. It focuses on research efforts on cancer escape, apoptosis and senescence and Immune surveillance. The company was founded in 2007 and is headquartered in Lyon, France. | Commercial Services |
Transgene, Inc. | |
Lyonbiopôle
Lyonbiopôle Miscellaneous Commercial ServicesCommercial Services Lyonbiopôle is a competitiveness cluster located in Lyon, France. The French company serves as a catalyst for the health innovation ecosystem by connecting, developing, and promoting it. Lyonbiopôle's main focus is on the health sector, and it works to ensure that the ecosystem is thriving and innovative. | Commercial Services |
Fondation FINOVI | |
Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd.
Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. engages in theresearch and development, and manufacture of immunotherapies for the treatment of oncology and infectious diseases. Its business scope includes biopharmaceutical technology development, technology transfer, and related technical advisory services. The company was founded on July 26, 2010 and is headquartered in Tianjin, China. | Commercial Services |
BioAster
BioAster Miscellaneous Commercial ServicesCommercial Services BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon. | Commercial Services |
Fabentech SAS
Fabentech SAS Medical/Nursing ServicesHealth Services Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France. | Health Services |
Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd. | |
NH TherAguix SAS
NH TherAguix SAS Pharmaceuticals: MajorHealth Technology NH TherAguix SAS operates as a biotechnology company. The firm develops a nanodrug against cancer called AGuIX based on nanometric structuring that allows intravenous injection and the combination of the following properties to fight tumors: targeting, imaging, and treating. The company was founded by G?raldine Le Duc, Olivier Tillement and Fran?ois Lux in on December 11, 2015 and is headquartered in Meylan, France. | Health Technology |
Jalon Therapeutics
Jalon Therapeutics Pharmaceuticals: MajorHealth Technology Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison. | Health Technology |